your initial deposit *subject to change and depends on individual circumstances.
Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners,...Read more
Oxford Pharmascience passes statins formulation milestoneJanuary 28 2013, 7:22am
Oxford Pharmascience (LON:OXP) has successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.
The company said it has proven in-vitro release under simulated human conditions.
The Safestat programme aims to reformulate the widely used molecules of atorvastatin and simvastatin into doses one quarter of the original dose without lowering the effectiveness of the cholesterol reducing drugs.
The statins market is a huge one, valued at more than US$29bn in 2009, but many patients report side effects from their use; reducing the dosage may enable more people to use the drugs.
"Completion of formulation development is a first important milestone in the Safestat programme and we are now ready to proceed to manufacture of GMP [good manufacturing practice] products for use in proof of concept clinical trials during 2013," said Marcelo Bravo, chief technology officer of Oxford Pharmascience.